Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia
暂无分享,去创建一个
B. Sorrentino | Y. Zong | S. Zhou | S. Zhou | S. Zhou | Yang Zong | Brian P. Sorrentino
[1] J. Schellens,et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. , 2005, Cancer research.
[2] R. Ren,et al. Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.
[3] Mariël Brok,et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. , 2004, Blood.
[4] P. Houghton,et al. Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro , 2004, Cancer Research.
[5] G. Ehninger,et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate , 2004, Leukemia.
[6] L. Ashman,et al. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. , 2003, Blood.
[7] Michael F. Clarke,et al. Applying the principles of stem-cell biology to cancer , 2003, Nature Reviews Cancer.
[8] T. Lu,et al. Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone. , 2003, BioTechniques.
[9] J. Melo,et al. Chronic myeloid leukemia--advances in biology and new approaches to treatment. , 2003, The New England journal of medicine.
[10] H. Mizoguchi,et al. Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line. , 2003, Cancer Letters.
[11] T. Furukawa,et al. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells , 2003, Cancer science.
[12] G. Daley,et al. Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL , 2003, Cell.
[13] J. Melo,et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. , 2003, Blood.
[14] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[15] W. Elmquist,et al. Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated Efflux , 2003, Journal of Pharmacology and Experimental Therapeutics.
[16] M. Zucchetti,et al. α1 Acid Glycoprotein Binds to Imatinib (STI571) and Substantially Alters Its Pharmacokinetics in Chronic Myeloid Leukemia Patients , 2003 .
[17] T. Furukawa,et al. Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519. , 2002, Cancer letters.
[18] G. Sauvageau,et al. Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system. , 2002, Blood.
[19] J. Schuetz,et al. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[20] J. Kuriyan,et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.
[21] G. Kéri,et al. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. , 2002, Biochimica et biophysica acta.
[22] R. Larson,et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.
[23] M. Baccarani,et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.
[24] R. Ilaria,et al. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. , 2001, Blood.
[25] H. Nakauchi,et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype , 2001, Nature Medicine.
[26] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[27] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[28] T. Lu,et al. Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo. , 2000, Blood.
[29] J. Melo,et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.
[30] George Q. Daley,et al. The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity , 1999, The Journal of experimental medicine.
[31] X Zhang,et al. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. , 1998, Blood.
[32] Jon C. Aster,et al. Efficient and Rapid Induction of a Chronic Myelogenous Leukemia-Like Myeloproliferative Disease in Mice Receiving P210 bcr/abl-Transduced Bone Marrow , 1998 .
[33] B. Sorrentino,et al. Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. , 1998, Blood.
[34] A. Nienhuis,et al. An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene. , 1998, Blood cells, molecules & diseases.
[35] P. Borst,et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[36] K. McDonagh,et al. Expression of retroviral vectors containing the human multidrug resistance 1 cDNA in hematopoietic cells of transplanted mice. , 1995, Blood.
[37] I. Roninson,et al. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells , 1991, Cell.
[38] Mariël Brok,et al. Imatinib mesylate ( STI 571 ) is a substrate for the breast cancer resistance protein ( BCRP ) / ABCG 2 drug pump , 2004 .
[39] T. Holyoake,et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.